ResMed (RMD) Peer Comparison
$232.94
$3.00
(1.30%)
As on 02-Nov-2026 16:00EST
Market cap
$35,558 Mln
Revenue (TTM)
$5,733 Mln
P/E Ratio
24.2
P/B Ratio
5.3
Div. Yield
1 %
Edit
| ResMed (RMD) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Danaher (DHR) | Intuitive Surgical (ISRG) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
35,558 | 262,217 | 180,946 | 166,594 | 152,620 |
Revenue ($ Mln) |
5,733 | 47,351 | 48,229 | 25,608 | 11,578 |
Net Profit ($ Mln) |
1,593.17 | 7,083.00 | 4,701.00 | 4,331.00 | 2,957.20 |
Net Margin (%) |
27.79 | 14.96 | 9.75 | 16.91 | 25.54 |
RoE (%) |
25.61 | 13.25 | 18.06 | 8.13 | 17.58 |
Price to Earnings |
24.24 | 37.40 | 38.87 | 39.24 | 54.27 |
Price-To-Book |
5.34 | 4.75 | 3.48 | 3.07 | 9.92 |
Income Statement ($ Mln)
| ResMed (RMD) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Danaher (DHR) | Intuitive Surgical (ISRG) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
5,653.44 | 44,557.00 | 44,328.00 | 24,568.00 | 10,064.70 |
|
Cost of Revenue
|
2,201.70 | 26,318.00 | 19,721.00 | 9,598.00 | 3,422.40 |
|
Gross Profit
|
3,451.74 | 18,239.00 | 24,607.00 | 14,970.00 | 6,642.30 |
|
Operating Expenses
|
1,543.28 | 10,129.00 | 16,586.00 | 9,833.00 | 3,696.80 |
|
Operating Profit (EBIT)
|
1,908.46 | 8,109.00 | 8,048.00 | 5,137.00 | 2,945.50 |
|
Other Income
|
-- | -- | -- | -- | -- |
|
Profit before Tax
|
1,919.42 | 7,267.00 | 8,466.00 | 4,233.00 | 3,311.40 |
|
Provision for Tax
|
396.12 | 547.00 | 1,942.00 | 619.00 | 434.80 |
|
Profit after Tax (Net Income)
|
1,523.29 | 6,737.00 | 6,524.00 | 3,614.00 | 2,856.00 |
|
Minority Interest
|
-- | 129.00 | 641.00 | 7.00 | 117.70 |
|
Consolidated Profit
|
1,400.72 | 6,704.00 | 6,524.00 | 3,614.00 | -- |
Liabilities ($ Mln)
| ResMed (RMD) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Danaher (DHR) | Intuitive Surgical (ISRG) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
6,585.39 | 53,407.00 | 52,130.00 | 52,534.00 | 17,824.00 |
|
Minority Interest
|
-- | 129.00 | 641.00 | 7.00 | 117.70 |
|
Non-Current Liabilities
|
985.45 | 41,618.00 | 17,446.00 | 24,123.00 | 683.30 |
|
Current Liabilities
|
1,395.11 | 15,189.00 | 16,496.00 | 6,807.00 | 2,006.20 |
|
Total Liabilities
|
8,965.95 | 110,343.00 | 86,713.00 | 83,464.00 | 20,631.20 |
Assets ($ Mln)
| ResMed (RMD) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Danaher (DHR) | Intuitive Surgical (ISRG) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
4,641.21 | 81,636.00 | 60,717.00 | 70,708.00 | 10,851.70 |
|
Current Assets
|
4,324.74 | 28,707.00 | 25,996.00 | 12,756.00 | 9,779.50 |
|
Total Assets
|
8,965.95 | 110,343.00 | 86,713.00 | 83,464.00 | 20,631.20 |
|
Total Debt*
|
825.92 | 39,385.00 | 15,067.00 | 18,418.00 | 302.80 |
|
Net Current Assets
|
2,929.63 | 13,518.00 | 9,500.00 | 5,949.00 | 7,773.30 |
Cashflow ($ Mln)
| ResMed (RMD) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Danaher (DHR) | Intuitive Surgical (ISRG) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
1,805.83 | 7,818.00 | 9,566.00 | 6,416.00 | 3,030.50 |
|
Cash Flow from Investing Activities
|
-545.20 | -4,047.00 | -2,422.00 | -1,196.00 | 665.80 |
|
Cash from Financing Activities
|
-1,007.03 | 1,801.00 | -6,309.00 | -2,961.00 | -2,364.10 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| ResMed (RMD) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Danaher (DHR) | Intuitive Surgical (ISRG) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
21.41 | 7.69 | 10.03 | 5.25 | 16.46 |
|
ROE (%)
|
24.27 | 13.08 | 13.07 | 7.08 | 16.67 |
|
ROA (%)
|
17.77 | 6.49 | 7.76 | 4.49 | 14.47 |
|
EBIT Margin (%)
|
-- | -- | -- | -- | -- |
|
Net Margin (%)
|
26.94 | 15.12 | 14.72 | 14.71 | 28.38 |
|
Cash Profit Margin (%)
|
-- | -- | -- | -- | -- |
Growth Ratios
| ResMed (RMD) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Danaher (DHR) | Intuitive Surgical (ISRG) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
0.10 | 0.04 | 0.06 | 0.03 | 0.21 |
|
EBIT Growth (%)
|
-- | -- | -- | -- | -- |
|
Net Profit Growth (%)
|
8.75 | 6.35 | -51.32 | -7.31 | 22.97 |
|
EPS Growth (%)
|
0.10 | 0.08 | -0.51 | -0.04 | 0.24 |
|
Book Value Growth (%)
|
-- | -- | -- | -- | -- |
Valuation Ratios
| ResMed (RMD) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Danaher (DHR) | Intuitive Surgical (ISRG) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
18.55 | 32.43 | 33.55 | 45.04 | 71.47 |
|
Price / Book Value
|
4.29 | 4.09 | 4.20 | 3.10 | 11.45 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
12.83 | 21.61 | 18.87 | 25.42 | 49.76 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| ResMed (RMD) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Danaher (DHR) | Intuitive Surgical (ISRG) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.13 | 0.74 | 0.29 | 0.35 | 0.02 |
|
Short term debt to equity ratio
|
0.04 | 0.07 | 0.06 | 0.00 | 0.00 |
|
Current Ratio
|
3.10 | 1.89 | 1.58 | 1.87 | 4.87 |
|
Quick Ratio
|
2.42 | 1.53 | 1.18 | 1.51 | 3.96 |
|
Interest Coverage
|
65.74 | 6.12 | 25.83 | 16.97 | -- |
Operating Efficiency Ratios
| ResMed (RMD) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Danaher (DHR) | Intuitive Surgical (ISRG) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
18.33 | 23.71 | 17.89 | 15.93 | 16.18 |
|
Asset Turnover
|
0.66 | 0.43 | 0.53 | 0.31 | 0.51 |
|
Receivable days
|
65.48 | 82.76 | 61.20 | 61.72 | 54.16 |
|
Inventory Days
|
155.40 | 72.19 | 117.44 | 91.69 | 177.54 |
|
Payable days
|
48.70 | 46.50 | 78.11 | 68.44 | 23.93 |
|
Cash Conversion Cycle
|
172.18 | 108.45 | 100.53 | 84.97 | 207.78 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
